Moh Tadayyon

Publications by Year

Research Areas

Pancreatic function and diabetes, Diabetes Treatment and Management, Metabolism, Diabetes, and Cancer, Diabetes and associated disorders, Peroxisome Proliferator-Activated Receptors

Most-Cited Works

• → 8-(3-(R)-Aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a Highly Potent, Selective, Long-Acting, and Orally Bioavailable DPP-4 Inhibitor for the Treatment of Type 2 Diabetes(2007)282 cited
• → (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a Novel Xanthine-Based Dipeptidyl Peptidase 4 Inhibitor, Has a Superior Potency and Longer Duration of Action Compared with Other Dipeptidyl Peptidase-4 Inhibitors(2008)278 cited
• → Minireview: Challenges and Opportunities in Development of PPAR Agonists(2014)161 cited
• → Inhibition of fatty acid synthase prevents preadipocyte differentiation(2005)136 cited
• → Mono‐unsaturated fatty acids protect against β‐cell apoptosis induced by saturated fatty acids, serum withdrawal or cytokine exposure(2004)105 cited
• → Differential protective effects of palmitoleic acid and cAMP on caspase activation and cell viability in pancreatic β-cells exposed to palmitate(2006)60 cited
• → 3,5-Dihydro-imidazo[4,5-d]pyridazin-4-ones: A class of potent DPP-4 inhibitors(2008)40 cited
• → Chronic Treatment with the Dipeptidyl Peptidase-4 Inhibitor BI 1356 [(R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione] Increases Basal Glucagon-Like Peptide-1 and Improves Glycemic Control in Diabetic Rodent Models(2008)31 cited
• → Expression and functional activity of PPARγ in pancreatic β cells(2004)29 cited
• → Insulin sensitisation in the treatment of Type 2 diabetes(2003)27 cited